ExoCoBio obtained a US Patent for Rose Stem Cell-derived Exosome (RSCE™)
Retrieved on:
Friday, May 19, 2023
SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- ExoCoBio, one of the top three exosome companies in the world, announced that it has obtained a patent (US Application No: 17/141,693) from the US Patent and Trademark Office for a cosmetic composition containing rose stem cell-derived exosomes or extracellular vesicles.
Key Points:
- SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- ExoCoBio, one of the top three exosome companies in the world, announced that it has obtained a patent (US Application No: 17/141,693) from the US Patent and Trademark Office for a cosmetic composition containing rose stem cell-derived exosomes or extracellular vesicles.
- In this patent, ExoCoBio used its proprietary technology ExoSCRT™ process to mass-culture stem cells derived from roses and isolate high-purity exosomes (RSCE™) from the culture medium.
- Various efficacy evaluations were performed on the mass-produced RSCE™, resulting in a significant increase in collagen production from human skin fibroblasts.
- In particular, with the most data and patents, ExoCoBio has been at the forefront of plant stem cell-derived exosome research worldwide.